|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF343 |
Gene summary for ZNF343 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF343 | Gene ID | 79175 |
| Gene name | zinc finger protein 343 | |
| Gene Alias | dJ734P14.5 | |
| Cytomap | 20p13 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q6P1L6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79175 | ZNF343 | LZE4T | Human | Esophagus | ESCC | 3.06e-21 | 5.31e-01 | 0.0811 |
| 79175 | ZNF343 | LZE24T | Human | Esophagus | ESCC | 1.46e-02 | 1.06e-01 | 0.0596 |
| 79175 | ZNF343 | P2T-E | Human | Esophagus | ESCC | 3.64e-15 | 1.13e-01 | 0.1177 |
| 79175 | ZNF343 | P8T-E | Human | Esophagus | ESCC | 3.03e-04 | 5.42e-02 | 0.0889 |
| 79175 | ZNF343 | P10T-E | Human | Esophagus | ESCC | 1.48e-13 | 1.00e-01 | 0.116 |
| 79175 | ZNF343 | P11T-E | Human | Esophagus | ESCC | 2.46e-02 | 1.16e-01 | 0.1426 |
| 79175 | ZNF343 | P12T-E | Human | Esophagus | ESCC | 3.37e-12 | 1.32e-01 | 0.1122 |
| 79175 | ZNF343 | P15T-E | Human | Esophagus | ESCC | 5.26e-03 | 8.41e-02 | 0.1149 |
| 79175 | ZNF343 | P16T-E | Human | Esophagus | ESCC | 1.42e-09 | 1.39e-01 | 0.1153 |
| 79175 | ZNF343 | P17T-E | Human | Esophagus | ESCC | 2.68e-03 | 1.43e-01 | 0.1278 |
| 79175 | ZNF343 | P20T-E | Human | Esophagus | ESCC | 2.18e-03 | 9.29e-02 | 0.1124 |
| 79175 | ZNF343 | P21T-E | Human | Esophagus | ESCC | 2.47e-04 | 8.58e-02 | 0.1617 |
| 79175 | ZNF343 | P22T-E | Human | Esophagus | ESCC | 9.42e-04 | 5.69e-02 | 0.1236 |
| 79175 | ZNF343 | P23T-E | Human | Esophagus | ESCC | 3.36e-03 | 9.60e-02 | 0.108 |
| 79175 | ZNF343 | P24T-E | Human | Esophagus | ESCC | 3.60e-05 | 6.68e-02 | 0.1287 |
| 79175 | ZNF343 | P26T-E | Human | Esophagus | ESCC | 5.21e-46 | 7.20e-01 | 0.1276 |
| 79175 | ZNF343 | P27T-E | Human | Esophagus | ESCC | 4.24e-04 | 4.51e-02 | 0.1055 |
| 79175 | ZNF343 | P28T-E | Human | Esophagus | ESCC | 2.11e-10 | 1.75e-01 | 0.1149 |
| 79175 | ZNF343 | P30T-E | Human | Esophagus | ESCC | 2.13e-03 | 1.46e-01 | 0.137 |
| 79175 | ZNF343 | P31T-E | Human | Esophagus | ESCC | 2.50e-06 | 8.93e-02 | 0.1251 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF343 | STM | Breast | ADJ | KRT16,DKK1,CRISPLD2, etc. | 4.54e-02 |  |
| ZNF343 | STM | Breast | Precancer | KRT16,DKK1,CRISPLD2, etc. | 1.96e-01 |  |
| ZNF343 | MYOFIB | Prostate | BPH | C10orf128,BIVM,FAM50B, etc. | 3.88e-01 |  |
| ZNF343 | ICAF | Prostate | BPH | C10orf128,BIVM,FAM50B, etc. | 8.31e-02 | |
| ZNF343 | ICAF | Prostate | Healthy | C10orf128,BIVM,FAM50B, etc. | 4.15e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF343 | SNV | Missense_Mutation | novel | c.1795T>A | p.Phe599Ile | p.F599I | protein_coding | deleterious(0) | probably_damaging(0.935) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF343 | SNV | Missense_Mutation | c.295C>T | p.Leu99Phe | p.L99F | protein_coding | tolerated(0.13) | benign(0.272) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ZNF343 | SNV | Missense_Mutation | c.1786G>A | p.Gly596Ser | p.G596S | protein_coding | deleterious(0) | possibly_damaging(0.814) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| ZNF343 | insertion | Frame_Shift_Ins | novel | c.1629_1630insGGGCCTCTTAGCTACTCCCC | p.Ser544GlyfsTer115 | p.S544Gfs*115 | protein_coding | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | |||
| ZNF343 | insertion | Frame_Shift_Ins | novel | c.1796_1797insC | p.Ser600Ter | p.S600* | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| ZNF343 | insertion | Frame_Shift_Ins | novel | c.1793_1794insGAGAGGGGCAAAGATGT | p.Phe599ArgfsTer59 | p.F599Rfs*59 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| ZNF343 | insertion | Frame_Shift_Ins | novel | c.1440_1441insG | p.Arg481GlufsTer9 | p.R481Efs*9 | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | |||
| ZNF343 | insertion | Nonsense_Mutation | novel | c.1439_1440insAAATTAGGTAAAGTGATTCAGATTAAAGGTGAAATAATTTATACA | p.Cys480delinsTer | p.C480delins* | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | |||
| ZNF343 | SNV | Missense_Mutation | novel | c.213N>A | p.Phe71Leu | p.F71L | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
| ZNF343 | SNV | Missense_Mutation | novel | c.143N>T | p.Cys48Phe | p.C48F | protein_coding | tolerated(0.09) | benign(0.029) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |